Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | https://onlinelibrary.wiley.com/doi/10.1002/ccd.31442 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Lack of Racial Disparities in Cangrelor Therapy in Patients Presenting With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention Waiel Abusnina Kalyan R. Chitturi Abhishek Chaturvedi Lior Lupu Dan Haberman Matteo Cellamare Vaishnavi Sawant Cheng Zhang Itsik Ben‐Dor Lowell F. Satler Hayder D. Hashim Brian C. Case Ron Waksman Catheterization and Cardiovascular Interventions ABSTRACTBackgroundCangrelor is an intravenous P2Y12 receptor antagonist that exerts rapid and potent antiplatelet effects. It is associated with a reduction in the indcidence of ischemic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI).AimsThe aim of our study was to investigate the racial disparities and their impact on outcomes among patients with ACS who were treated with cangrelor during PCI.MethodsWe reviewed the data of patients with ACS who were treated with cangrelor during PCI at our center from 2018 to 2023 and divided between African American (AA) and Caucasian patients. The primary safety outcome was in‐hospital thrombolysis in myocardial infarction (TIMI) major bleeding. The primary efficacy outcome was in‐hospital major adverse cardiac events (MACE), defined as a composite of cardiac death, MI, or stroke. Multivariate regression analysis was performed to assess the primary outcomes after controlling for differences in baseline characteristics.ResultsThe study included 1181 patients who received cangrelor during PCI for ACS, including 616 AA and 565 Caucasian patients. AA patients were significantly younger (61 ± 13 vs. 64 ± 12 years; p < 0.001) and had higher rates of hypertension, diabetes mellitus, and end‐stage renal disease requiring dialysis. There were no significant differences between AA and Caucasian patients regarding in‐hospital TIMI major bleeding (odds ratio [OR]: 0.55; 95% confidence interval [CI]: 0.16–1.88; p = 0.343) and in‐hospital MACE (OR: 1.82; 95% CI: 0.71–4.69; p = 0.212) after controlling for relevant baseline differences.ConclusionNo racial disparities were observed with regard to the administration of cangrelor during PCI in patients presenting with ACS, and cangrelor was not associated with increased bleeding for AA patients as compared to Caucasian patients. 10.1002/ccd.31442 http://onlinelibrary.wiley.com/termsAndConditions#vor